About Endurx
EnduRx, a virtual, pre-clinical company, is developing a peptide-directed nanoparticle drug delivery platform and therapeutics for hard-to-treat solid tumors and selected other indications.
Published foundational studies by an accomplished institutional team showed significant tumor volume reduction and sometimes complete tumor elimination. EnduRx is building on these studies to develop nanoparticles with improved efficacy, safety and robustness.
Tumor-specific delivery of highly-toxic chemotherapy agents and other APIs would offer reduced systemic toxicity and thereby improve both drug efficacy and patient experience. Improved patient experience can increase compliance well as quality-of-life during treatment, potentially further improving outcomes.
The EnduRx peptide-directed polymeric nanoparticle platform technology offers the potential to improve tumor-specific delivery of a range other approved therapeutics and developmental candidates. EnduRx seeks collaborations with other companies interested in application of our drug delivery platform to their molecule.
As a virtual pre-clinical company, EnduRx utilizes resources across the US in locations including Boston, Memphis, Houston, Tucson, Phoenix and Scottsdale, San Diego and elsewhere.
Corporate Office:
EnduRx Pharmaceuticals Inc.
8340 N Thornydale Rd Suite 110-328
Tucson, AZ 85741
phone: (855) 368-2878
(be prepared to leave a voicemail)
Please do not mail unsolicited materials to our Corporate Office address.
Contact should be initiated by email to
David Loynd, President & CEO:
dloynd at endurxpharm dot com
We welcome communication with the potential to add value but persistent unwanted solicitation and spam will be blocked.